Neumora Therapeutic NMRA 深 沪
等待开盘 04-01 09:30:00 美东时间
1.95
+0.020
+1.04%
华盛通- 最 高2.035
- 今 开1.91
- 成交量 315.58万股
- 最 低 1.89
- 昨 收 1.93
- 总市值 3.31亿
- 52周最高 3.65
- 市盈率 静 --
- 换手率 1.86%
- 52周最低 0.611
- 委 比 -48.32%
- 总股本 1.70亿
- 历史最高 21.00
- 量 比 2.58
- 振 幅 7.51%
- 历史最低 0.611
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Neumora Therapeutics Q4 EPS $(0.35) Misses $(0.33) Estimate
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 7.36 percent. This is a 5.41 percent increase over losses of $(0.37) per share
03-30 19:21
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
Neumora FY25 net loss narrows to $237 million; cash drops to $183 million
Neumora FY25 net loss narrows to $237 million; cash drops to $183 million Neumora posted a Q4 net loss of USD 59 million, with loss per share at USD 0.35. Full-year net loss narrowed to USD 237 million, with loss per share improving to USD 1.45. Operating loss widened to USD 241 million as R&D spend
03-30 18:53
Neumora Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Neumora Therapeutics, Inc. (NASDAQ:NMRA) will release earnings for the fourth q...
03-28 00:26
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
Neumora Therapeutics announced it will host a conference call and live webcast on March 30, 2026, at 8:00 a.m. ET to discuss its fourth quarter and full year 2025 financial results and provide a business update. A live webcast will be available on the Company’s website, www.neumoratx.com, with a replay archived for 30 days. Participants can register here. Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing nov...
03-16 11:00
LB Pharmaceuticals appoints Robert Lenz to board
LB Pharmaceuticals appoints Robert Lenz to board LB Pharmaceuticals appointed Robert Lenz, M.D., Ph.D. to its board of directors. Lenz most recently served as executive vice president and head of R&D at Neumora Therapeutics. Disclaimer: This news brief was created by Public Technologies (PUBT) using
03-09 20:01
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
LB Pharmaceuticals announces the appointment of Dr. Robert Lenz, a veteran neuroscientist with over 20 years of experience in drug development, to its Board of Directors. His expertise is expected to support the advancement of LB-102, a promising investigational therapy for neuropsychiatric disorders. Dr. Lenz brings extensive leadership experience from roles at major pharmaceutical companies, including Amgen and Neumora Therapeutics, where he ov...
03-09 12:00
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment
William Blair upgrades Neumora after strong Alzheimer's agitation data, sees upside from NMRA-511 and obesity pipeline potential.
02-18 03:32
William Blair Upgrades Neumora Therapeutics to Outperform
William Blair analyst Myles Minter upgrades Neumora Therapeutics (NASDAQ:NMRA) from Market Perform to Outperform.
02-17 23:21
美股牛股 | 生物技术公司EVMN飙涨超70%！新药用于治疗特应性皮炎的临床试验取得积极成果；ICHR涨超32%
生物技术公司EVMN飙涨超70%！新药用于治疗特应性皮炎的临床试验取得积极成果；ICHR涨超32%，Q4收入2.24亿美元超预期>>
02-11 15:44
